Please login to the form below

Not currently logged in
Email:
Password:

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.

Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.

At GW he will assume in the newly-created role of VP, clinical research, where he will lead clinical development, medical affairs, and regulatory activities related to the company's work in epilepsy, pain and other diseases.

GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis in Canada and the European Union in 2010. It is also in clinical trials for other indications, including cancer pain.

"This is an exciting time to be joining GW, with a number of important products currently under development for patients in the US including Sativex and Epidiolex,” said Dr Sommerville.

8th May 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics